Capuramycin Analogues for Selective DPAGT1 Inhibition in Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for DPAGT1-selective inhibitors to prevent cancer progression, as existing nucleoside antibiotics like tunicamycin are non-selective and toxic to healthy cells, while capuramycin has a narrow spectrum of activity and is less toxic but lacks specificity for DPAGT1.
Innovation Solution
Development of novel DPAGT1 inhibitors, such as capuramycin analogues, that exhibit anti-invasion and anti-metastasis activity against solid tumors by selectively targeting DPAGT1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tunicamycin is used to inhibit DPAGT1, then DPAGT1 inhibition is achieved, but selectivity is lost and toxicity to healthy cells increases
Solution Approach 1:
The patent applies local quality by modifying specific regions of the capuramycin molecule (positions 2, 4, 6 of the sugar ring and N-position of the amino acid) to create analogues with enhanced DPAGT1 selectivity. Each analogue has specific substituent groups (R1-R6) at defined positions that confer selective binding to DPAGT1 while sparing healthy cells, thus achieving localized improvement in selectivity without compromising overall efficacy
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations) of the capuramycin backbone to optimize DPAGT1 selectivity. The analogues feature different combinations of hydroxyl, halogen, alkyl, and aryl groups at specific positions, creating a series of compounds with tuned selectivity parameters that inhibit DPAGT1 effectively while reducing off-target toxicity
2Object-affected harmful factors
If capuramycin is used as an inhibitor, then toxicity to healthy cells is reduced, but selectivity for DPAGT1 is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor design into a stable capuramycin core structure (which provides low baseline toxicity) and variable substituent segments (R1-R6) that can be independently optimized for DPAGT1 selectivity. This modular approach allows the toxicological properties to be maintained from the parent compound while the selectivity is enhanced through targeted modifications of specific segments
Solution Approach 2:
The patent creates composite molecular structures by combining the capuramycin scaffold with various functional groups (halogens, hydroxyls, amino acids, aromatic rings) at specific positions. These composite analogues integrate the low-toxicity property of capuramycin with the DPAGT1-binding affinity of the added functional groups, achieving both reduced toxicity and enhanced selectivity simultaneously
Data Source
AI summary
Provided herein are compounds and methods of using these compounds to treat disorders related to DPAGT1 function, including cancer and bacterial infections.